No Data
No Data
No Data
No Data
No Data
Keqian Biotech (688526.SH): A total cost of 24.37 million yuan to buy back 0.3177% of the shares
Gelonghui, April 1 | Keqian Biotech (688526.SH) announced that as of March 31, 2024, the company had repurchased 1,481,214 shares of the company's shares through centralized bidding transactions, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24,372,261.54 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceApr 1 07:25 ET
Keqian Biology (688526.SH): A total of 1.4812 million shares have been repurchased
Gelonghui, March 1, 丨 Keqian Biotech (688526.SH) announced that as of February 29, 2024, the company had repurchased a total of 1.4812 million shares through the Shanghai Stock Exchange trading system, accounting for 0.3177% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.64 yuan/share, the lowest price was 16.22 yuan/share, and the total amount of capital paid was RMB 24.3723 million (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceMar 1 04:01 ET
Keqian Biotech (688526.SH): 0.11% share repurchase for the first time
Gelonghui, Feb. 27丨Keqian Biotech (688526.SH) announced that on February 27, 2024, the company repurchased 499,530 shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.11% of the company's total share capital of 466,168,016 shares. The highest price of the repurchase transaction was 16.62 yuan/share, the lowest price was 16.39 yuan/share, and the total amount of capital paid was RMB 8,242,245.00.
Gelonghui FinanceFeb 27 02:44 ET
Keqian Biotech (688526.SH) performance report: 2023 net profit of 418 million yuan increased 2.17% year over year
Gelonghui, Feb. 26: Keqian Biotech (688526.SH) announced the 2023 Annual Results Report. In 2023, the company achieved operating income of 1,066 billion yuan, an increase of 6.45% over the previous year; realized net profit attributable to owners of the parent company of 418 million yuan, an increase of 2.17% over the previous year.
Gelonghui FinanceFeb 26 04:49 ET
Keqian Biotech (688526.SH): Plans to spend 30 million yuan to 50 million yuan to buy back shares
On February 21, Gelonghui Biotech (688526.SH) announced that the company plans to buy back some of the company's issued RMB common shares (A shares) through centralized bidding transactions, all or part of them to implement employee stock ownership plans or equity incentives. The total capital of this repurchase is not less than RMB 30 million (inclusive) and not more than RMB 50 million (inclusive); the repurchase price is not more than RMB 20 per share (inclusive).
Gelonghui FinanceFeb 21 03:59 ET
Keqian Biology (688526.SH): Intends to sign a patent transfer contract with Huazhong Agricultural University
Gelonghui (688526.SH) announced on November 28, Keqian Biology () announced that after competitive negotiations with Huazhong Agricultural University, Huazhong Agricultural University has decided to transfer the patent for “a mutated strain of the swine epidemic diarrhea virus that does not depend on pancreatin and its construction and application” to the company, and plans to sign a patent transfer contract for the above patent. The company will have to pay 2 million yuan to Huazhong Agricultural University for the above patent transfer.
Gelonghui FinanceNov 28, 2023 03:25 ET
No Data
No Data